Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

Fig. 2

Effects of secukinumab on skin and musculoskeletal manifestations of psoriasis patients at risk to develop PsA. a Baseline and 24-week psoriasis area severity index (PASI), body surface area (BSA), and dermatology quality of life index (DLQI) in psoriasis patients at risk to develop PsA. b Baseline and 24-week visual analogue scale (VAS) for pain, VAS for global musculoskeletal disease activity, and psoriatic arthritis impact of disease (PSAID) in psoriasis patients at risk to develop PsA. c Correlation between total psoriatic arthritis magnetic resonance imaging score (PsAMRIS) and PASI score. d Correlation between total PsAMRIS and VAS for pain

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us